1Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA,2000,284(10):1247-1255.
2Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med, 2000,343(21):1520-1528.
3Deeks JJ,Smith LA,Bradley MD.Efficacy,tolerability,and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ, 2002,325(7365):619.
4Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol, 2002,89(6A):10D-17D.
5Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf, 2002,25(7):537-544.
7Mukherjee D,Nissen SE,Topol EJ.Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001,286(8):954-959.
8Ray WA, Stein CM, Daugherty JR, et al. Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. The Lancet,2002,360:1071-1073.
9Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosan-oids. J Pharmacol Exp Ther,1999,289(2):735-741.
10Mamdani M,Juurlink DN,Lee DS,et al.Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.Lancet,2004,363(9423):1751-1756.
